Stemrim Inc. (4599) Press Release
StemRIM Announces Patent Registration (Canada) for Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy, Old Myocardial Infarction
Earlier from Stemrim
- StemRIM Announces Patent Registration for Stem Cell Gene Therapy Technology (SR-GT1) Aimed at Curative Treatment of DEB in,South Korea
- [Delayed]Notice Regarding Recognition of Non-operating Income (Subsidy Income)
- StemRIM Announces Patent Registration (Australia) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
- StemRIM Announces Patent Registration (Russia) for Redasemtide, as a Therapeutic Indication for Fatty Liver and Non-alcoholic Steatohepatitis